CONTEXT: Publication of an RWE study in type 2 diabetes patients treated with SGLT2 and GLP1- receptor antagonists showing a long term reduction in risk of coronary heart disease | Single country data (Italy) from 312 patients
IMPACT: Medium
READ TIME: 3 mins
Quality Level Mean [1 – 10]: 8
1. “Italy: Both SGLT2 inhibitors and GLP1-receptor agonists reduce the 10-year risk for cardiovascular disease in type 2 diabetes (T2D) patients without baseline CHD, reveals data from real-world study.”
2. “Ernesto Maddaloni, Sapienza University of Rome, Italy, and colleagues aimed to evaluate the effect of glucagon-like peptide1 receptor-agonist (GLP1 RA) and sodium-glucose co-transporter2 inhibitor (SGLT2i) on the risk of coronary heart disease (CHD) in type 2 diabetes (T2D) in primary cardiovascular prevention, in this real-world study.”
3. “Key findings of the study include:. The 10-year CHD risk significantly decreased over 24 months in both GLP1 RA and SGLT2i groups, with 3% and 7% CHD risk reduction already obtained after the first 6 months of GLP1 RA and SGLT2i therapy respectively in both groups.”
4. “‘This real-world study shows that both GLP1 RA and SGLT2i reduce the 10-year risk for cardiovascular disease in patients with T2D in primary cardiovascular prevention,’ wrote the authors.”
5. “Reference:. The study titled, ‘Decrease of coronary heart disease risk with GLP1-receptor agonists or SGLT2 inhibitors therapy in patients with type 2 diabetes in primary cardiovascular prevention: A 24 months follow-up study,’ is published in the journal Diabetes Research and Clinical Practice.”